Renewal Application: Kidney Health Initiative (R18) Clinical Trials Optional
ID: 353918Type: Posted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Food and Nutrition

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353918

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-041.html
Timeline
    Description

    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Renewal Application: Kidney Health Initiative (R18) Clinical Trials Optional" to support the American Society of Nephrology (ASN) in advancing kidney health research. The initiative aims to enhance the administrative and scientific infrastructure of the Kidney Health Initiative (KHI), facilitating research, project management, and collaboration among stakeholders in nephrology. This funding is crucial for improving medical product evaluations related to kidney diseases and fostering innovative research projects that can significantly impact patient care outcomes. Interested applicants must submit Letters of Intent by June 3, 2024, with full applications due by July 3, 2024, for a potential funding amount of up to $350,000 annually, contingent upon performance and appropriations. For further inquiries, contact Terrin Brown at terrin.brown@fda.hhs.gov.

    Point(s) of Contact
    terrin.brown@fda.hhs.gov
    Files
    Title
    Posted
    RFA-FD-24-041.html
    The Department of Health and Human Services, through the U.S. Food and Drug Administration (FDA), has released a Notice of Funding Opportunity (NOFO) titled “Renewal Application: Kidney Health Initiative (R18) Clinical Trials Optional” (FON: RFA-FD-24-041). The purpose is to continue funding the American Society of Nephrology (ASN) for the Kidney Health Initiative (KHI), promoting kidney health research and improving medical product evaluations related to kidney diseases. The funding aims to support KHI's administrative and scientific infrastructure and includes activities like conducting research, project management, and collaborative projects with diverse stakeholders in nephrology. Key deadlines include the submission of Letters of Intent by June 3, 2024, and applications due by July 3, 2024, with potential funding of up to $350,000 annually for five years, contingent upon satisfactory performance and appropriations. The document outlines specific eligibility criteria for applicants, including that only ASN is eligible, and emphasizes adherence to application instructions. Review criteria for applications focus on scientific merit, innovation, and the potential impact of proposed projects. The NOFO reinforces FDA's commitment to fostering collaborative environments to advance kidney health and improve patient care outcomes through innovative research projects.
    Similar Opportunities
    Innovative Approaches for Reducing Disparities in Kidney Health
    Active
    Office of the Assistant Secretary for Health
    The Office of the Assistant Secretary for Health is forecasting a federal grant opportunity titled "Innovative Approaches for Reducing Disparities in Kidney Health" aimed at addressing chronic kidney disease (CKD) disparities through community-based strategies. This grant will support demonstration projects that adapt evidence-based approaches to reduce CKD and its related risk factors, particularly focusing on groups disproportionately affected by these health issues. With an estimated total program funding of $2 million, the agency anticipates awarding four grants, each ranging from $425,000 to $500,000, with applications due by February 11, 2025. Interested applicants can reach out to Alana Sutherland at OMHGrants@hhs.gov or by phone at 301-945-3668 for further information.
    Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)," aimed at establishing Recruitment Sites (RS) for enrolling individuals with Type 1 diabetes (T1D) who are at risk of nephropathy. This initiative seeks applications for a longitudinal cohort study that will involve obtaining kidney biopsies and conducting comprehensive clinical phenotyping, with a focus on ethical practices and inclusivity to enhance understanding of T1D nephropathy and identify potential therapeutic targets. The funding opportunity has a budget of approximately $1.3 million, with individual awards of up to $400,000 in direct costs annually, and key deadlines include a letter of intent due on November 11, 2024, with applications closing on December 10, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.
    Polycystic Kidney Disease Core Centers (U54 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Polycystic Kidney Disease (PKD) Core Centers through a Notice of Funding Opportunity (NOFO) aimed at enhancing national research efforts in PKD. The initiative seeks to establish four Core Centers that will collaborate within the PKD Research Resource Consortium, focusing on developing and sharing essential research tools and resources while promoting scientific diversity and engagement among a wide range of investigators. Approximately $3.44 million in funding is anticipated for FY 2025, with applications due by November 15, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    DoD Kidney Cancer, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Kidney Cancer Research Program (KCRP) Clinical Trial Award, aimed at supporting innovative clinical trials that can significantly impact kidney cancer treatment and management. The program encourages proposals that range from preliminary proof-of-concept trials to large-scale studies, emphasizing the need for robust preliminary data, access to suitable patient populations, and necessary materials for the trials. With an estimated total program funding of $6.4 million and the expectation of awarding approximately two grants, interested applicants must submit a pre-application letter of intent by September 24, 2024, and a complete application by October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)." This initiative aims to support the development of innovative tools and technologies that address significant challenges in kidney, urologic, and hematologic research, encouraging high-risk, exploratory projects that differ from traditional R01 grants. The funding, with a maximum budget of $275,000 over two years, is open to a diverse range of eligible applicants, including various educational institutions and community organizations, with applications due by January 7, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html.
    KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 - Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) to support exceptional graduate students transitioning into postdoctoral roles focused on Kidney, Urology, or Hematology (KUH) research. This funding opportunity aims to recruit talented individuals from diverse fields such as engineering, data science, and genetics, while excluding those already engaged in KUH research. The program provides funding for up to two years for dissertation research (F99 phase) and four years of mentored postdoctoral training (K00 phase), with stipends, tuition, and allowances for living costs. Interested applicants must adhere to specific eligibility criteria and are encouraged to contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries. The application deadline is April 1, 2025, and further details can be found at the provided link: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-033.html.
    Central Coordinating Site for the Polycystic Kidney Disease Research Core Centers (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for the Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research Core Centers through Funding Opportunity Number RFA-DK-25-015. The CCS will collaborate with four PKD Research Core Centers to enhance understanding of PKD and promote resource sharing, providing essential administrative support, managing data sharing, and administering pilot project funding. This initiative is crucial for fostering a diverse and collaborative research environment to address the challenges of PKD effectively. The funding opportunity anticipates approximately $1.1 million for one award in FY 2025, with annual budgets around $350,000. Interested applicants must submit their proposals via Grants.gov by November 14, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)." This grant aims to support translational research that justifies later-phase therapeutic discovery and development efforts related to diseases such as obesity, diabetes, digestive disorders, and kidney diseases. The initiative encourages innovative research on novel small molecules and biologics, with a focus on therapeutics that significantly improve or differentiate from existing treatments. NIH anticipates awarding 3-4 grants annually, with budgets ranging from $250,000 to $300,000 per project for up to five years. Interested applicants must submit their proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. Additional details can be found at http://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html.
    DoD Kidney Cancer, Translational Research Partnership Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Kidney Cancer Translational Research Partnership Award, a federal grant aimed at fostering collaborative research partnerships between clinicians and research scientists to advance kidney cancer treatment and care. This opportunity encourages the development of translational research projects that address significant problems in kidney cancer, requiring partnerships that include one clinician and one research scientist who contribute equally to the research design and execution. With an estimated total program funding of $7.68 million, the program anticipates awarding approximately six grants, each with a maximum budget of $800,000 over a three-year period. Interested applicants must submit a pre-application letter of intent by September 24, 2024, followed by a full application due by October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.